Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed as far as the frustration. I thought for sure this would go to $10 post approval given they had already secured a loan and done a capital raise.
Bottom line the products and potential look great but until management restores some faith that they know what they're doing and can execute effectively the growth in front of them the share price will languish.
Murocman
Should get some news soon. Between MACI launch and DCM regulatory feedback and/or partnership news, I'd think it won't be quiet for long.
GLTA,
Murocman
Volume alert. Over daily average in 1st 30 minutes of trading.
Murocman
TENX - Phase III data for LEVO-CTS Trial due this month. Drug already approved outside of North America (Simdax) and has been used in over 1 million patients so success of trial is de-risked.
$50M market cap
28M shares outstanding, 17M Float
Almost 40% institutional ownership with likes of Sabby, Broadfin and Baker Brothers.
Stock just over $2 with 52-wk range of $1.21-2.94.
Could be a mover on positive data.
GLTA,
Murocman
Hi Ash,
Do you when the next earnings are due. Am traveling so can't look it up.
TIA,
Murocman
That is the million dollar question. Hopefully??
Murocman
$IMUC$ making a move on volume today with no news.
Murocman
Market either doesn't like the financing or the label. Last trade at $7.75!
Murocman
Big volume and price spike all of a sudden.
Murocman
$EGLT$ moving higher all of a sudden on a volume spike.
Murocman
TENX...according to their Nov 18th press release, it's this month:
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it has completed patient enrollment for its Phase 3 LEVO-CTS trial in cardiac surgery.
The Company will lock its database after 30-day follow-up from the final patient, and currently expects to report top-line results in January 2017 in conjunction with the study’s lead investigators at Duke Clinical Research Institute (DCRI).
GLTU,
Murocman
TENX-moving up on volume. Ph III trial data due this month.
Murocman
Positive CF Results:
http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-newsArticle&ID=2233305
Let's see if we can rally here.
GLTA,
Murocman
Thanks...yeah I found that yesterday. There is a link to it at biopharmcatalyst website-FDA Calendar section.
I guess I'd be surprised if they didn't hear something by the end of January.
Murocman
Arymo-there has been a lot of buzz and expectation that the company should hear from the FDA before the end of the year.
However I see nothing in any of the company or FDA PR's and documents that confirms that.
Am wondering how long this might drag out?
Murocman
Standard price action for biotechs to gap to a high and pull back from that level throughout the first day of trading on a binary event.
Once the flippers are out of the way, the price many times makes much more significant moves in the following days. Go back and look at the charts for AQXP and CPXX and you'll see what I mean. Volume and accumulation strong here. Looking for similar action in the next 4-6 weeks.
GLTU,
Murocman
You call 47M share volume no interest! That's funny. Lot's of institutional buying today. Short-mid term this goes above $5.
If they announce a DCM partnership, the lid blows off this thing. If you have even a little patience, this may be a very lucrative opportunity.
GLTA,
Murocman
Why do you say that? We may still get a bit more run. Am looking to lighten up a bit by early next week.
Murocman
Wouldn't be surprised at all to see it come early given the holidays. Could be a few as 3 weeks IMO.
Murocman
Solid consolidation of gains today. I'm liking the price-volume action at the moment.
GLTA,
Murocman
If no takeover or partnership news by mid December, I'd be leery of one. Per the final paragraph of the last earnings release, the company stated they have enough working capital to make it to 31 December 2016.
Let's hope our knight in shining armor (Pfizer) sweeps the company up in an all cash so we don't have to worry!
GLTA,
Murocman
Newsmax article on Cannabis investing:
http://www.newsmax.com/Newsfront/cannabis-market-share-investors/2016/11/23/id/760402/
GLTA,
Murocman
The company will run out of cash by the end of the year, so I'd expect a deal by mid-December or they're going to have to raise cash to keep the lights on.
The trading the next couple of weeks will be interesting IMO.
Murocman
NVCR$ Anybody done any research or follow Novacure (NASDAQ: NVCR). I stumbled across it today and am starting some DD. Looks like it could be a mover in early December.
The company is expected to release trial data Dec 7th and Dec 12th.
They already have two approved products and revenue is growing.
Chart looks OK and definitely room to run with good data. Institutional ownership is decent.
GLTA,
Murocman
That's the first day the FDA will be back open after the New Year's holiday. I think there's a fair to middling chance we hear something before year end.
GLTA,
Murocman
Just read the earnings call transcript. I'd think that if a deal is going to get done in the near term, it would need to be in place VERY soon as the company is going to run out of cash end of December.
To me the main investment gamble is not if there is a partnership/asset sale/buyout, it's whether or not it happens in the next couple of weeks, or there is more dilution in December and the payoff comes in Q1/Q2 of 2017?
Murocman
Conference call after market closes. Possible trial update and catalyst.
Murocman
VCEL...news is out. Positive secondary endpoint data for their cardio therapy. No noticeable stock reaction. Guess we'll have to wait the MACI pre-approval run-up.
GLTA,
Murocman
VCEL...there is supposed to be a presentation today at 2PM ET for their cardio treatment. May see news PM today?
GLTA,
Murocman
Presentation is still listed on the AHA Scientific Sessions website, 2-3:15 on Monday. It says the abstract is embargoed at this time.
Maybe that explains why no mention about it on the earnings call?
Murocman
Thank you for posting. Sounds like there is definitely optimism about Q4 and MACI approval.
Interesting there was zero discussion about their upcoming presentation next week. Either a non-event or they want to save the surprise?
If the former, this may languish as far as share price until mid-late December.
GLTA,
Murocman
Not exactly breathtaking numbers. Any good nuggets from the conference call?
GLTA,
Murocman
If remember correctly, they are low on cash and likely need to make a licensing or buyout deal very soon to be able to follow through with filing for approval?
Could be a very interesting next six weeks!
GLTA,
Murocman
Volume alert. Upcoming earnings call and recent milestone payment have attracted some interest,
GLTA,
Murocman
I think earnings will serve as a catalyst to get this back moving in the right direction.
They are generating good revenue and seem to be well run. Anticipation of approval of MACI and positive exposure on thier Heart Failure therapy ought to all contribute to a nice turnaround in the remainder of Q4.
GLTA,
Murocman
We should see earnings and a corporate update o/a 9 Nov. Probably not a catalyst in itself but will provide visibility on the fact that they generate revenues and highlight upcoming value and share price drivers.
GLTA,
Murocman
Q3 Earnings and corporate update should be out.
GLTU,
Murocman
CERC...Found that as well. Also did a bit more digging. This is a second Ph II trial. First one at lower dose failed, so they're trying again with a higher dose. Safety profile is good.
Certainly risk here but may run a bit as there is some chatter this compound could be better in that it more directly targets MDD.
Thanks for the DD and GLTU!
Murocman
Yup! May be a good runner into this event.
Murocman
CERC. Top line Phase II data for their Major Depressive Disorder drug is due in November per company PR on 9/21/16.
I thought for some reason it was early November, but the PR only specifies during the month.
Murocman